In a report released today, David Turkaly from JMP Securities reiterated a Buy rating on Paragon 28 (FNA – Research Report), with a price target of $30.00. The company’s shares closed yesterday at $16.75.
Turkaly covers the Healthcare sector, focusing on stocks such as Paragon 28, Steris, and Apyx Medical. According to TipRanks, Turkaly has an average return of 4.9% and a 51.26% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Paragon 28 with a $29.50 average price target.
See the top stocks recommended by analysts >>
FNA market cap is currently $1.56B and has a P/E ratio of -44.26.
Based on the recent corporate insider activity of 46 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of FNA in relation to earlier this year. Most recently, in October 2022, Rosenthal Lee, an Insider at FNA sold 691,774.00 shares for a total of $13,175,856.98.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Paragon 28 Inc is a medical devices company that develops, distributes, and sells medical devices in the foot and ankle segment of the orthopedic implant marketplace. Its products include plates and plating systems, screws, staples, and nails aimed to address all major foot and ankle procedures including ankle, charcot, fracture fixation, hallux valgus, hammertoe, and flatfoot.
Read More on FNA:
